# Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

> **NCT06172205** · PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 262 (estimated)

## Conditions studied

- BCLC Stage C Hepatocellular Carcinoma
- Chemotherapy Effect

## Interventions

- **DRUG:** intravenous FOLFOX7 plus Camrelizumab and apatinib
- **DRUG:** HAIC-FOLFOX plus Camrelizumab and apatinib

## Key facts

- **NCT ID:** NCT06172205
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 262 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06172205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06172205, "Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT06172205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*